Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

Expression of G1/S-phase cell cycle regulators were evaluated alongside EGFR in breast cancer. The authors conjugated cetuximab with CDK inhibitor SNS-032, for specific delivery to EGFR-expressing cells and assessed antibody drug conjugate internalization, and its anti-tumor functions in vitro and in orthotopically-grown basal-like/TNBC xenografts.
[Clinical Cancer Research]
AbstractPress Release